Bank7: Century's Deposits Fix The Funding Squeeze And Drive EPS Accretion

Bank7 Corp. is rated Buy, with its Century Financial acquisition expected to add $1.23B in low-cost deposits and support loan growth. The deal is projected to deliver 23–27% EPS accretion by 2027, with pro forma EPS of $5.75–$5.95 and a 1.7-year tangible book value earnback. Bank7 also reports a 21.4% ROATCE, a 38.1% efficiency ratio, and 17.2% annual TBV per-share growth from 2021 to 2025.

Analysis

The investment case hinges less on headline EPS accretion than on whether acquired deposits stay inexpensive as they are redeployed into loans. If deposit pricing rises or loan growth requires looser underwriting, the projected earnings benefit can shrink while credit costs and integration risk persist. The claimed accretion and TBV earnback are forward estimates, not independently established outcomes; verify deal terms, deposit retention and beta, pro forma share count, and credit performance before underwriting them.

Over the next 1–3 months, deal approvals, closing timing, and any updated integration guidance are the key catalysts. Over 6–18 months, the test is whether loan growth converts into durable returns without weakening credit quality or deposit economics. Regional-bank peers could face pressure to defend deposits or pursue acquisitions, but the same competition may erase the cost advantage assumed in BSVN’s case.

The contrarian point: strong historical profitability does not guarantee attractive incremental returns on a larger balance sheet. Without valuation and deal-term detail, the article supports a positive operating watchlist view, not a high-conviction buy. A worsening deposit mix, weaker-than-guided accretion, or rising credit deterioration would falsify the thesis.

Key Decisions for Investors

• Avoid chasing BSVN solely on projected 2027 accretion; first compare the current valuation with the pro forma earnings outlook and confirm the acquisition’s financing, dilution, and closing assumptions.
• Track quarterly deposit retention and deposit costs against loan yields, alongside nonperforming assets and net charge-offs. Treat deterioration in these measures as an early warning that growth is being purchased at the expense of returns or credit quality.
• Consider a staged long in BSVN only after deal terms and closing conditions are verified, with position risk capped around execution and credit uncertainty; there is not enough information here to set a defensible entry price or target.
• Reassess if management lowers the accretion outlook, integration or regulatory timing slips materially, or deposit pricing rises enough to undermine the claimed low-cost funding advantage.